North America Biotechnology Market Size and Forecast 2025–2033

The North America Biotechnology Market is entering a defining decade of scientific breakthroughs, strategic investments, and expanding cross-sector applications. According to Renub Research, the market is projected to grow from US$ 532.72 billion in 2024 to US$ 1,592.68 billion by 2033, registering a robust CAGR of 12.94% from 2025 to 2033.

This impressive growth trajectory reflects the region’s powerful combination of strong R&D investments, cutting-edge technological innovation, expanding personalized medicine demand, supportive regulatory ecosystems, and deep collaborations between pharmaceutical giants and biotech pioneers.

From gene-editing platforms to regenerative medicine, biotechnology is not only transforming healthcare—it is reshaping agriculture, industrial processing, and environmental sustainability across North America.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=north-america-biotechnology-market-p.php

North America Biotechnology Industry Overview

Biotechnology is the scientific discipline that harnesses biological systems, living organisms, or cellular components to develop products and technologies that improve human life and environmental health. By merging biology with technological advancement, the field has unlocked transformative solutions in medicine, agriculture, and industry.

Applications span a wide range of innovations, including:

·        Biopharmaceutical development

·        Vaccine production

·        Genetic engineering

·        Crop modification

·        Renewable biofuels

·        Sustainable biomaterials

·        Disease diagnostics

By manipulating DNA sequences and cellular functions, biotechnology addresses critical global challenges such as healthcare access, food security, and climate change. In North America, the sector has become a cornerstone of scientific progress and economic expansion.

The region’s biotechnology leadership is supported by:

·        Advanced healthcare infrastructure

·        Strong academic research networks

·        Venture capital availability

·        Favorable government policies

·        Strategic partnerships between biotech and pharmaceutical firms

These elements collectively position North America as the epicenter of global biotech innovation.

Key Growth Drivers

1. Expanding Applications Across Industries

While biotechnology initially centered on pharmaceuticals and diagnostics, its scope has broadened significantly.

Healthcare Biotechnology
Biotech continues to drive advances in gene therapy, regenerative medicine, monoclonal antibodies, and vaccine development. Precision therapies are improving patient outcomes in oncology, autoimmune diseases, and rare genetic disorders.

Agricultural Biotechnology
Genetically modified crops enhance productivity, climate resilience, and pest resistance. These innovations are increasingly essential as climate variability intensifies.

Industrial Biotechnology
Bioprocessing technologies enable sustainable production of biodegradable plastics, biofuels, and green chemicals—accelerating the transition toward a bio-based economy.

Environmental Biotechnology
Bioremediation techniques help manage pollution and waste, contributing to sustainability goals.

Additionally, synthetic biology and computational modeling now allow scientists to design tailored biological systems, opening entirely new industrial frontiers. This cross-sector adaptability is a core engine of market growth.

2. Rising Demand for Personalized Medicine

Personalized medicine has become a transformative force within North America’s healthcare ecosystem. This approach customizes treatment strategies based on a patient’s genetic profile, environmental exposure, and lifestyle factors.

Advancements in genomics and molecular diagnostics now allow clinicians to:

·        Identify genetic mutations linked to diseases

·        Predict drug response

·        Tailor therapies for improved outcomes

The declining cost of genetic sequencing has made these technologies increasingly accessible. As chronic and inherited diseases continue to rise, both patients and healthcare providers are embracing individualized treatments.

Biotech companies across the United States and Canada are investing heavily in targeted therapies, biomarker-based diagnostics, and gene-editing platforms—creating vast commercial opportunities.

3. Advancements in Genomic and Proteomic Technologies

Genomics and proteomics form the scientific backbone of modern biotechnology.

·        Genomics analyzes complete genetic sequences.

·        Proteomics studies protein structures, functions, and interactions.

Together, they enable deeper understanding of disease mechanisms and therapeutic targeting.

Technologies such as:

·        Next-generation sequencing (NGS)

·        CRISPR-Cas9 gene editing

·        Advanced bioinformatics

·        AI-driven biomarker discovery

have dramatically accelerated research timelines and improved precision.

In July 2023, a notable agreement between Pfizer Inc. and Alexion and AstraZeneca Rare Disease strengthened efforts to advance preclinical gene therapy products, demonstrating industry commitment to next-generation genomic therapeutics.

Such collaborations reinforce North America’s competitive edge in precision-based treatment development.

Market Challenges

High Research and Development Costs

Despite its growth potential, biotechnology remains one of the most capital-intensive industries.

Developing a new biopharmaceutical product can:

·        Take more than a decade

·        Cost billions of dollars

·        Carry high failure risk during clinical trials

Smaller biotech firms often depend on venture capital, mergers, or strategic partnerships with larger pharmaceutical companies to survive lengthy development cycles. The financial burden remains a major barrier to entry and innovation.

Regulatory Hurdles

Regulatory oversight is essential for ensuring product safety and efficacy, yet it can also slow market momentum.

In the United States, the U.S. Food and Drug Administration enforces strict approval processes. Similarly, Health Canada maintains rigorous standards.

Lengthy clinical trial requirements, evolving biosafety regulations, and ethical considerations around gene editing can delay product launches. Cross-border regulatory differences across North America further complicate commercialization strategies.

While necessary for public health, these frameworks can create bottlenecks—particularly for emerging biotech startups.

United States Biotechnology Market

The United States remains the global leader in biotechnology innovation and commercialization.

Key strengths include:

·        Advanced R&D infrastructure

·        Deep venture capital ecosystem

·        Strong university-industry collaboration

·        Favorable intellectual property frameworks

The country is at the forefront of gene therapy, biologics manufacturing, immunotherapy, and AI-driven drug discovery. However, high operational costs and intense competition pose ongoing challenges.

Strategic investments continue to reinforce U.S. dominance. In April 2025, Novartis AG announced a USD 23 billion investment plan to strengthen its U.S. biotech and pharmaceutical footprint, including seven new facilities and thousands of jobs.

Similarly, Amgen Inc. committed an additional USD 900 million to expand its Ohio biologics manufacturing site, citing a favorable business climate.

In March 2025, F. Hoffmann-La Roche AG launched the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus, enhancing AI-driven drug discovery capabilities.

These developments highlight the U.S. market’s resilience and continued expansion.

Canada Biotechnology Market

Canada’s biotechnology sector is steadily advancing, supported by strong academic institutions, skilled scientific talent, and government-backed research initiatives.

Focus areas include:

·        Biopharmaceuticals

·        Genomics research

·        Regenerative medicine

·        Environmental biotechnology

Canadian regulatory pathways often provide expedited approvals, encouraging innovation. Export potential and global partnerships further strengthen the market.

However, compared to the United States, Canada faces limitations in domestic funding scale and talent retention. Despite these constraints, the country remains highly competitive in vaccine research and precision medicine innovation.

Recent Industry Developments

The North American biotechnology sector has witnessed significant strategic activity:

·        June 2025: Eli Lilly agreed to acquire Verve Therapeutics for USD 1.3 billion to strengthen its gene-editing pipeline.

·        June 2025: Illumina completed its USD 425 million acquisition of SomaLogic, expanding into proteomics and multi-omics capabilities.

·        October 2023: Gilead Sciences, Inc. partnered with Assembly Biosciences to develop advanced therapeutics targeting severe viral diseases.

·        July 2023: Bertis launched its Pan-omics Analysis Service & Solution (PASS) in the United States, integrating AI-powered bioinformatics into precision medicine services.

These transactions demonstrate how mergers, acquisitions, and partnerships are accelerating innovation while strengthening competitive positioning.

Market Segmentation

By Product Type

·        Instruments

·        Reagents

·        Software and Services

By Technology

·        Nanobiotechnology

·        Tissue Engineering and Regeneration

·        DNA Sequencing

·        Cell-Based Assays

·        Fermentation

·        PCR Technology

·        Chromatography

·        Others

By Application

·        Healthcare

·        Food and Agriculture

·        Natural Resources and Environment

·        Industrial Processing

·        Bioinformatics

·        Others

By Country

·        United States

·        Canada

Key Players Analysis

Major companies shaping the North American biotechnology landscape include:

·        Lonza Group AG

·        Amgen Inc.

·        Syngenta AG

·        Biocon Limited

·        Biogen Inc.

·        F. Hoffmann-La Roche AG

·        Novartis AG

·        Novo Nordisk A/S

·        Pfizer Inc.

·        Seagen Inc.

Each company has been evaluated from five perspectives:

1.     Company Overview

2.     Key Persons

3.     Recent Developments & Strategies

4.     SWOT Analysis

5.     Sales Analysis

Their strategic expansions, R&D intensity, and global partnerships continue to shape the competitive ecosystem.

Final Thoughts

The North America Biotechnology Market stands at a pivotal moment. With Renub Research projecting growth from US$ 532.72 billion in 2024 to US$ 1,592.68 billion by 2033, the sector is set to nearly triple in value within a decade.

Scientific breakthroughs in genomics, proteomics, gene editing, and AI-driven bioinformatics are reshaping medicine and beyond. Expanding applications across agriculture, environmental management, and industrial biotechnology further strengthen the industry’s growth narrative.

While high R&D costs and regulatory complexities remain significant challenges, sustained investments, strategic collaborations, and technological innovation are propelling the region forward.

North America is not merely participating in the biotech revolution—it is leading it. As innovation accelerates and personalized healthcare becomes mainstream, biotechnology will remain one of the most transformative and economically powerful industries of the 21st century.